Of great interest, MYC-translocated Burkitt lymphomas showed more sensitive to CS2164 treatment than DLBCL and mantel cell lymphomas (32), prompting us to investigate the effect of CS2164 alone or in combination with the BCL2 inhibitor venetoclax on the MYC-translocated HGBL-DHL. This evidence concerns the gene BCL2 and Burkitt lymphoma.